The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Beyonttra (acoramidis), from Germany’s Bayer (BAYN: DE), to treat adult patients with cardiomyopathy (damage to the heart muscle) caused by variant or wild-type transthyretin amyloidosis (ATTR-CM).
Acoramidis has been approved via a fast-track approval process for medicines, known as the International Recognition Procedure (IRP), following approval by the European Medicines Agency (EMA) earlier this year.
Developed by US genetic diseases and cancer drug company BridgeBio Pharma (Nasdaq: BBIO), Beyonttra was licensed to Bayer to commercialize acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze